SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

Renewed tariff threats against European allies, stemming from the Greenland situation, are currently dominating market discourse for SPY and impacting futures. While some investors anticipate a significant market pullback, many view any dip as a familiar "buy the dip" opportunity, expecting a rapid recovery as markets have previously navigated similar geopolitical "drama". The community is actively debating the potential for broader trade implications and forthcoming economic and political developments to shape near-term direction.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as renewed tariff threats regarding Greenland trigger market volatility, with the community sharply divided between those anticipating a significant correction and "buy the dip" proponents. Investors are weighing escalating geopolitical tensions and rising treasury yields against historical market resilience and expectations for a robust tech earnings season.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Shares of Trump Media & Technology Group are trending as recent statements from Donald Trump regarding Greenland's acquisition and associated tariff threats on European nations spark intense debate. The community is actively discussing the geopolitical implications and potential market volatility, with sentiment largely driven by reactions to these prominent political headlines.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is experiencing significant recent volatility and a notable pullback, sparking intense community debate. While bulls highlight strong fundamental growth from its AI-powered AXON platform and recent analyst upgrades as a "buy the dip" opportunity, bears point to circulating short report rumors and broader ad-tech sector weakness, alongside discussions of options market dynamics, as reasons for the sharp decline. This creates a highly active discussion about the stock's near-term direction ahead of upcoming earnings.

Volatility Shares Trust - 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF

Volatility Shares 2x Long VIX Futures ETF (UVIX) is seeing intense discussion as escalating geopolitical tensions, from US actions in Venezuela and Greenland to EU tariff disputes and potential escalations with Iran and China, fuel expectations for a market-wide fear spike. Traders are actively positioning for a major upward move in volatility, leveraging UVIX for short-term hedges while widely acknowledging its pronounced decay characteristics make it unsuitable for extended holding.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is trending with high investor enthusiasm following international approvals for its Anktiva treatment in both lung and bladder cancers, notably a first-in-world non-chemo combo for lung cancer from Saudi Arabia. This significant progress, coupled with reported substantial revenue growth, is generating widespread community discussion about the company's transformative potential in oncology and fueling considerable short squeeze speculation due to high short interest. Investors are closely monitoring further global regulatory developments and anticipating a paradigm shift in cancer treatment as Dr. Patrick Soon-Shiong actively promotes the company's innovative "BioShield" platform.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is drawing attention following recent developments in its pipeline, including the acquisition of VLX-1005 and ongoing progress for its lead anticoagulant, tecarfarin, notably through a collaboration with Abbott for pivotal trials. Community discussion is split between excitement over its potential in treating rare cardiovascular conditions and concerns regarding dilution and the need for substantial financing for upcoming clinical milestones. Its ultra-low float is also a key talking point, contributing to observed volatility and the potential for significant price action.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MULN CRYPTO is trending due to a mix of strong skepticism and active promotion, with many users questioning its legitimacy and connection to the controversial Mullen Automotive stock, often cited as a past "scam." While some in the community label it "garbage" and warn of further losses, a dedicated segment is actively calling for accumulation and anticipating significant price surges for the "Mullen Army" token on the Solana network.

ProShares Trust - ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF

ProShares VIX Short-Term Futures ETF ($VIXY) is trending as renewed discussions around escalating geopolitical tensions, potential government actions like tariffs, and broader market overvaluation fuel expectations for increased volatility. The community is actively debating whether current market conditions warrant a substantial spike in volatility, with many viewing $VIXY as a critical hedge against potential market shifts.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

Natural Gas prices are surging dramatically, driven by widespread forecasts for an intense Arctic blast across the US, with many in the community anticipating a significant short squeeze and a substantial gap-up for BOIL when markets open. Traders are actively debating whether these substantial gains will hold, given the highly volatile nature of leveraged natural gas ETFs like BOIL.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totaling 10,924,303 shares, a growth of 43.1...

Immuneering (NASDAQ:IMRX) Insider Acquires $10,501.86 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall acquired 2,298 shares of the stock in a transaction that occurred on Thursday, January 15th. The shares were bought...

Insider Buying: Immuneering (NASDAQ:IMRX) Insider Purchases 2,298 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Brett Matthew Hall purchased 2,298 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was...

Immuneering (NASDAQ:IMRX) Insider Purchases $10,897.90 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Leah Neufeld bought 2,626 shares of Immuneering stock in a transaction on Tuesday, January 13th. The shares were acquired at an average...

Immuneering (NASDAQ:IMRX) Insider Acquires $10,897.90 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) insider Leah Neufeld bought 2,626 shares of Immuneering stock in a transaction dated Tuesday, January 13th. The shares were acquired at an...

Immuneering (NASDAQ:IMRX) Director Buys $87,000.00 in Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Peter Feinberg bought 20,000 shares of the business's stock in a transaction dated Monday, January 12th. The shares were acquired at...

Insider Buying: Immuneering (NASDAQ:IMRX) Director Acquires 20,000 Shares of Stock

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) Director Peter Feinberg acquired 20,000 shares of the firm's stock in a transaction on Monday, January 12th. The shares were acquired at an...

Iridian Asset Management LLC CT Makes New $1.93 Million Investment in Immuneering Corporation $IMRX

Iridian Asset Management LLC CT bought a new position in Immuneering Corporation (NASDAQ:IMRX - Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The fund...

<ul class="summary-bullets"><li>The company reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP.</li><li>The combination showed 94% and 83% overall survival at 6 months and 9 months.</li><li>Immuneering is now looking to start dosing the first patient in the pivotal late-stage trial in mid-2026.</li></ul>Immuneering Corporation (IMRX) on Wednesday said that its experimental drug improved overall survival in a mid-stage trial in patients with first-line pancreatic cancer, causing the stock to close 24% higher.The company was studying atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company reported 64% overall survival at 12 months in first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP, compared to a 35% overall survival rate observed in patients given standard of care treatment.The combination showed 94% and 83% overall survival at 6 months and 9 months, both higher than the survival rate seen in patients receiving standard of care. The company also confirmed an overall response rate of 39% at 12 months for the combination, compared to 23% response rate in standard of care patients. Overall Survival (OS) in cancer is the length of time from diagnosis or start of treatment until death from any cause, serving as the "gold standard" measure for a treatment's effectiveness by showing if it helps patients live longer.&nbsp;However, no head-to-head clinical trial has been conducted evaluating atebimetinib and other candidates or products, the company clarified.<h2 class="st-heading-2">Safety Concerns</h2>Atebimetinib + mGnP continued to demonstrate a favorable tolerability profile in the patient population in the trial, with only two categories of adverse events observed at the Grade 3 level, the company said. No new safety signals were identified.The company is now looking to start dosing the first patient in the pivotal late-stage trial in mid-2026. In the latter half of the year, the company is also looking to dose the first patient with atebimetinib in combination with Libtayo in non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around IMRX stayed at ‘extremely bullish’ levels while message volume rose ‘high’ to ‘extremely high' levels.&nbsp; <a href="https://stocktwits.com/symbol/IMRX">IMRX stock</a> has gained nearly 253% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/revolution-medicines-stock-soars-on-report-of-abbvie-takeover/cmxzObIR42q">Revolution Medicines Stock Drops After-Hours On AbbVie Denying Acquisition Talks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Immuneering logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IMRX Stock Closed Over 20% Higher Today: Here’s Why

The company was studying atebimetinib in combination with modified gemcitabine/nab-paclitaxel. 

Equity

The company was studying atebimetinib in combination with modified gemcitabine/nab-paclitaxel. 


Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Rating of "Moderate Buy" from Analysts

Immuneering Corporation (NASDAQ:IMRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eight analysts that are covering the firm, MarketBeat.com reports. One...

Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. Its pipeline of drug candidates focuses on treating aspects of disease that have eluded conventional approaches, including cancer cachexia and metastasis. The company was founded by Robert J. Carpenter and Benjamin J. Zeskind in 2008 and is headquartered in Cambridge, MA.

IMRX
Immuneering Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IMRX News

IMRXImmuneering Corp